ABSTRACT
Background The inflammatory response within the central nervous system is a key driver of secondary brain injury after hemorrhagic stroke, both in patients with intracerebral hemorrhage (ICH) and aneurysmal subarachnoid hemorrhage (aSAH). In this study, we aimed to characterize inflammatory molecules in the blood and cerebrospinal fluid (CSF) of patients within 72 hours of hemorrhage to understand how such molecules vary across disease types and disease severity.
Methods Biological samples were collected from patients admitted to a single-center Neurosciences Intensive Care Unit with a diagnosis of ICH or aSAH between 2014 and 2022. Control CSF samples were collected from patients undergoing CSF diversion for normal pressure hydrocephalus. A panel of immune molecules in the plasma and CSF samples was analyzed using Cytometric Bead Array assays. Clinical variables, including demographics, disease severity, and intensive care unit length of stay were collected.
Results Plasma and/or CSF samples were collected from 260 patients (188 ICH patients, 54 aSAH patients, 18 controls). C-C motif chemokine ligand-2 (CCL2), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF), were detectable in the CSF within the first 3 days after hemorrhage, and all were elevated compared to plasma. Compared with controls, CCL2, IL-6, IL-8, G-CSF, and VEGF were elevated in the CSF of both ICH and aSAH patients (p<0.01 for all comparisons). VEGF was increased in ICH patients compared to aSAH patients (p<0.01). CCL2, G-CSF, and VEGF in the CSF were associated with more severe disease in aSAH patients only.
Conclusions Within 3 days of hemorrhagic stroke, proinflammatory molecules can be detected in the CSF at higher concentrations than in the plasma. Early concentrations of some pro-inflammatory molecules may be associated with markers of disease severity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Sansing received support related to this work from NIH/NINDS (R01NS097728). Dr. Magid-Bernstein received support related to this work from the Neurocritical Care Society (AWD0007451) and the American Heart Association (23CDA1054469).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Yale School of Medicine IRB, and consent was obtained from patients or their legally authorized representative.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
A deidentified version of the data is available upon request.
Non-standard Abbreviations and Acronyms
- ICH
- intracerebral hemorrhage
- aSAH
- aneurysmal subarachnoid hemorrhage
- DCI
- delayed cerebral ischemia
- CSF
- cerebrospinal fluid
- EVD
- external ventricular drain
- CCL2
- C-C motif chemokine ligand-2
- IL-6
- interleukin-6
- G-CSF
- granulocyte-colony stimulating factor
- IL-8
- interleukin-8
- VEGF
- vascular endothelial growth factor
- CNS
- central nervous system
- NPH
- normal pressure hydrocephalus
- IL-1β
- interleukin-1 beta
- IL-4
- interleukin-4
- MIP-1α
- macrophage inflammatory protein-1 alpha
- IL-10
- interleukin-10
- TNF-α
- tumor necrosis factor alpha
- IL-17
- interleukin-17
- ICU
- Intensive Care Unit
- GCS
- Glasgow Coma Scale
- IQR
- interquartile range
- ANOVA
- analysis of variance